Ligand: The Small Cap Powering Gilead's Remdesivir, , on October 5, 2020 at 9:47 pm

Financial News
By
On October 5, 2020
In Financial News
Tags:

President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: REGN) and remdesivir, an antiviral treatment from Gilead Sciences (NASDAQ: GILD).About Remdesivir: The FDA approved remdesivir for emergency use in May. Remdesivir was shown to shorten the recovery time for patients in the hospital with COVID-19.In June, Gilead announced the pricing of remdesivir: $390 per vial. The average five day treatment uses six vials, which would cost $2,340. Gilead has shown that the treatment can shorten the hospital stay of patients by four days, or $12,000 in hospital costs.On Monday, Trump announced that he would be leaving Walter Reed Hospital later in the day.The doctors said Trump received three treatments of remdesivir and would receive a fourth before leaving the hospital. A fifth treatment of remdesivir will be given at the White House.Captisol The Key Ingredient: Captisol, which is owned by Ligand Pharmaceuticals (NASDAQ: LGND), is a chemical structure that makes products soluble. Captisol is a key ingredient in remdesivir.Ligand is supplying Captisol to Gilead and partners that are making the generic version in 127 low- and middle-income countries. Ligand has extended its supply agreement with Gilead until 2030.Ligand announced in September that Captisol was seeing more growth than predicted in the company’s already bullish predictions. “The global medical need for Captisol-enabled drugs has never been higher,” said Ligand CEO John Higgins.Ligand forecast $200 million in Captisol sales for 2021. This marks the highest levels in the history of Captisol. Ligand has been investing in increasing production to support demand for the substance. “We continue to be pleased with the momentum relating to Captisol, as it is a critical component in multiple life-saving medicines,” Higgins said.Manufacturing partner Hovione is now producing more Captisol per month than it previously produced on an annual basis.In its second-quarter earnings release, Ligand said it was growing its annual production for Captisol from 60 metric tons to 500 metric tons.Captisol is a major component in several approved drugs. They include Kyprolis, from Amgen Inc (NASDAQ: AMGN); Nexterone from Baxter International (NYSE: BAX); Zultresso from Sage Therapeutics (NASDAQ: SAGE); and Evomela from Acrotech Biopharma and Casi Pharmaceuticals (NASDAQ: CASI).Kyprolis brings annual sales of $1.04 billion for Amgen as an approved drug to treat multiple myeloma.Financials: Ligand reported Captisol sales of $24.5 million for the second quarter. This total was made up primarily of sales for remdesivir. This was a large increase from the $8.5 million reported in the prior year’s second quarter.The strong second quarter led to Ligan raising its full-year revenue guidance to $165 million based on Captisol sales of $65 million to $90 million.The company’s initial guidance for the current fiscal year was revenue of $121 million and Captisol sales of $35 million.In the last fiscal year, Capitsol sales totaled $31.5 million. Royalty revenue for the company was $47 million. Total revenue for the last fiscal year was $120.3 million.What’s Next: Ligand will host a virtual investor day Oct. 20. The company will likely provide an update on Captisol sales and highlight its pipeline.Benzinga’s Take: Ligand operates with a “shots on goal” methodology. The company partners with many drug companies and licenses out its technology. In return, it may receive milestone payments, licensing revenue, royalty revenue or equity in the company.Captisol has been a strong performer for the company, and the huge demand seen from remdesivir could take Ligand’s revenue even higher than projected.LGND Price Action: The stock gained 3.2% in Monday’s session, closing at $100.26. Ligand shares have traded between $57.24 and $127.80 over the last fifty-two weeks.Photo courtesy of Gilead. See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Barstool Sports CEO Erika Nardini Elected To WWE’s Board * Founded By Tesla, SpaceX Engineers, Battery Maker Romeo Power Finds SPAC(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.,

Ligand: The Small Cap Powering Gilead's RemdesivirPresident Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: REGN) and remdesivir, an antiviral treatment from Gilead Sciences (NASDAQ: GILD).About Remdesivir: The FDA approved remdesivir for emergency use in May. Remdesivir was shown to shorten the recovery time for patients in the hospital with COVID-19.In June, Gilead announced the pricing of remdesivir: $390 per vial. The average five day treatment uses six vials, which would cost $2,340. Gilead has shown that the treatment can shorten the hospital stay of patients by four days, or $12,000 in hospital costs.On Monday, Trump announced that he would be leaving Walter Reed Hospital later in the day.The doctors said Trump received three treatments of remdesivir and would receive a fourth before leaving the hospital. A fifth treatment of remdesivir will be given at the White House.Captisol The Key Ingredient: Captisol, which is owned by Ligand Pharmaceuticals (NASDAQ: LGND), is a chemical structure that makes products soluble. Captisol is a key ingredient in remdesivir.Ligand is supplying Captisol to Gilead and partners that are making the generic version in 127 low- and middle-income countries. Ligand has extended its supply agreement with Gilead until 2030.Ligand announced in September that Captisol was seeing more growth than predicted in the company’s already bullish predictions. “The global medical need for Captisol-enabled drugs has never been higher,” said Ligand CEO John Higgins.Ligand forecast $200 million in Captisol sales for 2021. This marks the highest levels in the history of Captisol. Ligand has been investing in increasing production to support demand for the substance. “We continue to be pleased with the momentum relating to Captisol, as it is a critical component in multiple life-saving medicines,” Higgins said.Manufacturing partner Hovione is now producing more Captisol per month than it previously produced on an annual basis.In its second-quarter earnings release, Ligand said it was growing its annual production for Captisol from 60 metric tons to 500 metric tons.Captisol is a major component in several approved drugs. They include Kyprolis, from Amgen Inc (NASDAQ: AMGN); Nexterone from Baxter International (NYSE: BAX); Zultresso from Sage Therapeutics (NASDAQ: SAGE); and Evomela from Acrotech Biopharma and Casi Pharmaceuticals (NASDAQ: CASI).Kyprolis brings annual sales of $1.04 billion for Amgen as an approved drug to treat multiple myeloma.Financials: Ligand reported Captisol sales of $24.5 million for the second quarter. This total was made up primarily of sales for remdesivir. This was a large increase from the $8.5 million reported in the prior year’s second quarter.The strong second quarter led to Ligan raising its full-year revenue guidance to $165 million based on Captisol sales of $65 million to $90 million.The company’s initial guidance for the current fiscal year was revenue of $121 million and Captisol sales of $35 million.In the last fiscal year, Capitsol sales totaled $31.5 million. Royalty revenue for the company was $47 million. Total revenue for the last fiscal year was $120.3 million.What’s Next: Ligand will host a virtual investor day Oct. 20. The company will likely provide an update on Captisol sales and highlight its pipeline.Benzinga’s Take: Ligand operates with a “shots on goal” methodology. The company partners with many drug companies and licenses out its technology. In return, it may receive milestone payments, licensing revenue, royalty revenue or equity in the company.Captisol has been a strong performer for the company, and the huge demand seen from remdesivir could take Ligand’s revenue even higher than projected.LGND Price Action: The stock gained 3.2% in Monday’s session, closing at $100.26. Ligand shares have traded between $57.24 and $127.80 over the last fifty-two weeks.Photo courtesy of Gilead. See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Barstool Sports CEO Erika Nardini Elected To WWE’s Board * Founded By Tesla, SpaceX Engineers, Battery Maker Romeo Power Finds SPAC(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

+65 3105 1295

Taiwan

Coming Soon!

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Follow Us

Market Coverage